A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
Michael B. Lilly , Chunli Wu , Yu Ke , Wen-Pin Chen , Adam C. Soloff , Kent Armeson , Noriko N. Yokoyama , Xiaotian Li , Liankun Song , Ying Yuan , Christine E. McLaren , Xiaolin Zi
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (3) : e1627
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
• The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. • Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. • Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration with docetaxel/ADT.
docetaxel / lycopene / phase I trial / prostate cancer
2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |
PDF
